CJC-1295 DAC GHRH-R Research: Extended Receptor Engagement and Cell Model Studies

CJC-1295 DAC GHRH-R Research: Extended Receptor Engagement and Cell Model Studies

CJC-1295 DAC represents a structurally modified growth hormone-releasing hormone analog extensively studied in cell-based assay formats for its enhanced GHRH receptor (GHRH-R) pharmacology. This research compound incorporates a Drug Affinity Complex (DAC) modification that significantly alters its binding kinetics and receptor engagement profiles in controlled laboratory environments. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under standardized experimental conditions.

Receptor Pharmacology and Mechanism of Action

GHRH Receptor Binding Characteristics

CJC-1295 DAC functions as a selective GHRH receptor agonist, targeting the class B G-protein coupled receptor responsible for growth hormone-releasing hormone signaling. In vitro binding assays demonstrate that the compound maintains high affinity for GHRH-R while exhibiting modified pharmacokinetic properties through its DAC conjugation. The albumin-binding modification creates a reversible, non-covalent association that extends the compound's residence time in experimental systems.

Competitive binding studies using radiolabeled ligands reveal that CJC-1295 DAC competes effectively with native GHRH for receptor occupancy. The binding affinity (Ki) values obtained from cell-based competition assays indicate nanomolar potency comparable to endogenous GHRH, while demonstrating enhanced stability in serum-containing culture media.

Gs/cAMP/PKA Signaling Pathway Activation

Upon GHRH receptor binding, CJC-1295 DAC initiates canonical Gs protein-coupled signaling cascades in transfected cell models. Activation of adenylyl cyclase leads to rapid cyclic adenosine monophosphate (cAMP) accumulation, measurable through time-resolved fluorescence immunoassays and enzymatic detection methods. Peak cAMP responses typically occur within 10-15 minutes of compound exposure in HEK293 cells expressing recombinant GHRH receptors.

Downstream protein kinase A (PKA) activation follows predictable kinetics, with phosphorylation of CREB (cAMP response element-binding protein) serving as a reliable endpoint in cell-based functional assays. Western blot analysis of phospho-CREB levels provides quantitative measurement of pathway engagement across concentration ranges.

In Vitro Assay Systems and Cell Models

Primary Cell Culture Studies

Pituitary cell cultures derived from laboratory animals provide physiologically relevant models for studying CJC-1295 DAC pharmacology. Primary somatotroph cultures maintain endogenous GHRH receptor expression patterns and demonstrate dose-dependent responses to compound exposure. Flow cytometry analysis reveals receptor density variations between cell populations, allowing for correlation with functional responses.

Enzyme-linked immunosorbent assays (ELISA) measuring growth hormone release from cultured pituitary cells serve as standard functional endpoints. Concentration-response curves typically exhibit EC50 values in the low nanomolar range, consistent with high-affinity receptor binding data.

Recombinant Cell Line Applications

Stable cell lines expressing recombinant human GHRH receptors provide standardized platforms for pharmacological characterization. CHO-K1 and HEK293 cell models transfected with GHRH-R constructs enable precise control of receptor density and eliminate confounding variables present in primary cell systems.

Real-time monitoring of cAMP accumulation using bioluminescent reporter systems allows for kinetic analysis of receptor activation. These assays reveal the extended duration of signaling associated with DAC modification, distinguishing CJC-1295 DAC from unmodified GHRH analogs.

Albumin Binding and Extended Residence Time

Protein Interaction Studies

The DAC modification consists of a reactive lysine residue that forms reversible covalent bonds with serum albumin. Surface plasmon resonance (SPR) analysis quantifies this interaction, revealing association and dissociation rate constants that explain the compound's extended pharmacological activity in cell culture systems.

Albumin binding studies using purified bovine serum albumin demonstrate saturable, high-affinity interactions with dissociation constants in the micromolar range. This binding serves as a depot mechanism, gradually releasing active compound for continued GHRH receptor engagement.

Stability and Degradation Kinetics

Enzymatic stability assays using peptidases common in cell culture environments show enhanced resistance to proteolytic degradation compared to unmodified GHRH. High-performance liquid chromatography (HPLC) analysis tracks compound integrity over extended incubation periods, revealing minimal degradation in serum-supplemented media.

Research Summary

CJC-1295 DAC demonstrates distinct pharmacological properties in cell-based research systems, characterized by high-affinity GHRH receptor binding, robust Gs/cAMP/PKA pathway activation, and extended biological activity through albumin association. The compound maintains nanomolar potency in functional assays while exhibiting enhanced stability and prolonged receptor engagement compared to native GHRH. These characteristics make CJC-1295 DAC a valuable research tool for investigating GHRH receptor pharmacology and downstream signaling mechanisms in controlled in vitro environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML